TY - JOUR AB - A 61-year-old man with progressive prostate cancer after initial hormonal therapy was treated with TNP-470, an experimental agent with potent antiangiogenesis properties. During the period of TNP-470 treatment, the concentration of serum prostate-specific antigen (PSA) rapidly increased from 28.4 to 89.9 ng/ml. After termination of TNP-470 therapy, the concentration of PSA decreased from 89.9 to 10.3 ng/ml. This pattern of PSA change was previously unanticipated and may eventually provide additional insight into the pharmacological actions of TNP-470. AD - LOUISIANA STATE UNIV,MED CTR,DEPT MED,CTR EXCELLENCE CANC RES TREATMENT & EDUC,SHREVEPORT,LA 71130. AU - SARTOR,O DA - 1995/11/01 DO - 10.3892/or.2.6.1101 EP - 1102 IS - 6 JO - Oncol Rep PY - 1995 SN - 1021-335X 1791-2431 SP - 1101 ST - PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470) T2 - Oncology Reports TI - PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470) UR - https://doi.org/10.3892/or.2.6.1101 VL - 2 ER -